Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Assessment

The legacy of general health and science information has long provided a foundational framework for understanding how pharmaceutical interventions interact with human physiology. Within this broad context, the dissemination of knowledge regarding medication side effects has evolved from generalized warnings to more targeted risk assessments. This heritage emphasizes the importance of evidence-based communication, where the balance between therapeutic benefit and potential harm is carefully weighed. As the scientific community has refined its focus, particular attention has turned to the long-term implications of bisphosphonate therapies, such as Fosamax, which are commonly prescribed for bone density disorders. The transition from a general health perspective to a more specific occupational exposure concern arises when considering populations that may encounter heightened risks due to their professional environments. For instance, healthcare workers, dental professionals, or pharmaceutical manufacturing personnel might have sustained contact with these compounds, either through direct handling or environmental exposure. This shift in focus does not negate the broader health context but rather narrows the lens to examine how routine occupational settings could influence the likelihood of adverse outcomes, such as osteonecrosis of the jaw. By bridging from general health literacy to workplace-specific scenarios, the discussion now pivots to the nuanced interplay between medication exposure and occupational risk factors, setting the stage for a more detailed exploration of causation without delving into mechanistic specifics.

Bridging to Occupational and Clinical Risk Factors

Building on the general health context, it is essential to bridge to the specific clinical and occupational risk factors associated with Fosamax. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling. A recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies to rule out other causes. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The mechanistic pathways linking Fosamax to ONJ are rooted in bisphosphonate pharmacology. Bisphosphonates like alendronate accumulate in bone tissue, particularly at sites of high turnover such as the jaw. They inhibit osteoclast activity, reducing bone resorption and remodeling. This suppression of normal bone turnover can impair the jawbone's ability to repair microdamage and respond to local stressors, such as dental procedures or infection. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Research using estrogen-deficient rats treated with alendronate has examined effects on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These studies suggest that bisphosphonate treatment alters the mechanical and structural integrity of the jawbone, potentially predisposing it to necrosis under conditions of stress or infection.

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that the risk of ONJ may increase with duration of exposure to bisphosphonates and that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide guidance to healthcare providers and patients about the potential risk, though the label does not specify a precise threshold for risk or mandate routine dental screening before initiating therapy. For affected patients, causation-related considerations involve assessing the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates establishing a direct causal link in individual cases, as ONJ can also occur spontaneously in the absence of bisphosphonate use. However, the label notes that most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in some patients. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that not all cases are attributable to the drug.

Timeline, Management, and Summary of Evidence

The timeline between exposure and documented harm is variable. ONJ can develop within days to months after starting Fosamax, but it may also occur after years of use. The risk appears to increase with longer duration of bisphosphonate therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, conservative debridement, infection control, and avoidance of further invasive dental procedures. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, scientific evidence supports a causal association between Fosamax and osteonecrosis of the jaw, mediated by bisphosphonate-induced suppression of bone remodeling in the jawbone. The risk is influenced by duration of exposure, dental procedures, and other comorbidities. Warnings in the prescribing information address this risk, though individual causation requires careful evaluation of temporal and clinical factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

Scientific evidence shows that Fosamax (alendronate) can cause osteonecrosis of the jaw (ONJ) through suppression of bone remodeling. Bisphosphonates accumulate in the jawbone, inhibit osteoclast activity, and impair repair of microdamage. Animal studies have demonstrated altered mechanical and structural integrity of the jawbone (https://pubmed.ncbi.nlm.nih.gov/40345077/). Clinical data indicate that ONJ occurs more frequently with longer duration of use and after dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk increases with longer duration of bisphosphonate therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.